Cargando…

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy

INTRODUCTION: Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in cancer....

Descripción completa

Detalles Bibliográficos
Autores principales:	Raza, Afsheen, Merhi, Maysaloun, Inchakalody, Varghese Philipose, Krishnankutty, Roopesh, Relecom, Allan, Uddin, Shahab, Dermime, Said
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102435/ https://www.ncbi.nlm.nih.gov/pubmed/32220256 http://dx.doi.org/10.1186/s12967-020-02306-y

Ejemplares similares

Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report
por: Merhi, Maysaloun, et al.
Publicado: (2020)

Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report
por: Merhi, Maysaloun, et al.
Publicado: (2018)

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
por: Relecom, Allan, et al.
Publicado: (2021)

Role of Epstein–Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target
por: Fernandes, Queenie, et al.
Publicado: (2018)

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy
por: Taib, Nassiba, et al.
Publicado: (2023)

Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer
por: Raza, Afsheen, et al.
Publicado: (2022)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
por: Maalej, Karama Makni, et al.
Publicado: (2023)

Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
por: Fernandes, Queenie, et al.
Publicado: (2022)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
por: Dermime, Said, et al.
Publicado: (2021)

Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
por: Akbar, Shayista, et al.
Publicado: (2023)

Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells
por: Prabhu, Kirti S., et al.
Publicado: (2017)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma
por: Iura, Kunio, et al.
Publicado: (2015)

Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers
por: Raghavendra, Ashwini, et al.
Publicado: (2018)

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study
por: Matković, Božica, et al.
Publicado: (2011)

Transient expression of the cancer/testis cancer antigen NY-ESO-1 in Nicotiana benthamiana using a PVX-based viral vector
por: Lacorte, Cristiano, et al.
Publicado: (2014)

Clinicopathological Assessment of Cancer/Testis Antigens NY-ESO-1 and MAGE-A4 in Highly Aggressive Soft Tissue Sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma
por: Hudolin, Tvrtko, et al.
Publicado: (2013)

Centrosomal Localisation of the Cancer/Testis (CT) Antigens NY-ESO-1 and MAGE-C1 Is Regulated by Proteasome Activity in Tumour Cells
por: Pagotto, Anna, et al.
Publicado: (2013)

Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status
por: Shiohama, Yasuo, et al.
Publicado: (2017)

Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products
por: Siveen, Kodappully S., et al.
Publicado: (2018)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
por: Zhou, Hong, et al.
Publicado: (2023)

Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma
por: Gjerstorff, Morten F, et al.
Publicado: (2013)

Editorial: Genomics, proteomics and immunological signatures as diagnostic, predictive, and prognostic biomarkers in head and neck cancers
por: Raza, Afsheen, et al.
Publicado: (2023)

Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer
por: Milne, Katy, et al.
Publicado: (2008)

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
por: Raza, Afsheen, et al.
Publicado: (2023)

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

Cancer stem-like cells with increased expression of NY-ESO-1 initiate breast cancer metastasis
por: Liu, Mai-Ying, et al.
Publicado: (2019)

Guggulsterone Induces Apoptosis in Multiple Myeloma Cells by Targeting High Mobility Group Box 1 via Janus Activated Kinase/Signal Transducer and Activator of Transcription Pathway
por: Akhtar, Sabah, et al.
Publicado: (2022)

Prognostic impact of p53 and/or NY‐ESO‐1 autoantibody induction in patients with gastroenterological cancers
por: Hoshino, Isamu, et al.
Publicado: (2020)

Curcumin Induces Apoptotic Cell Death via Inhibition of PI3-Kinase/AKT Pathway in B-Precursor Acute Lymphoblastic Leukemia
por: Kuttikrishnan, Shilpa, et al.
Publicado: (2019)

Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling
por: Akhtar, Sabah, et al.
Publicado: (2019)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fau9i7n270md6f45ipa79jdef3